Gulf War Illness Clinical Trial
Official title:
Effects of Botanical Microglia Modulators in Gulf War Illness
Verified date | March 2024 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall objective of this protocol is to test if Gulf War Illness (GWI) involves chronic inflammation that cannot be measured with typical techniques. The investigators will be observing the effects of nine different botanical compounds (supplements) that are known to suppress inflammation. If one of those supplements helps the symptoms of GWI, it will give the investigators information about what is wrong in people with GWI.
Status | Completed |
Enrollment | 39 |
Est. completion date | September 2022 |
Est. primary completion date | September 2019 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 39 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male 2. Age 39-65, inclusive 3. Veterans who meet the Kansas inclusion criteria for GWI 4. Present in Persian Gulf between 1990 and August 1991 5. Patient completes daily report during 2 week baseline period (at least 80% completion rate) 6. Able to receive a venous blood draw Exclusion Criteria: 1. Positive rheumatoid factor at screening 2. Positive anti-nuclear antibody at screening 3. C-reactive protein> 3mg/L at screening 4. Erythrocyte Sedimentation Rate> 40mm/hr at screening 5. Auto-immune disorder 6. Diagnosed Rheumatologic Condition 7. Major PTSD symptoms 8. Hypotension (under 90/60 mm Hg) or history of cardiovascular disease 9. Antihypertensive, anticoagulant medication, nitroglycerine, lithium medication use 10. Diabetes with Hemoglobin A1C >9% 11. History of anaphylaxis to study botanical compounds 12. Current daily use of opioid medication 13. Hospital Anxiety and Depression Scale, Depression subscale score of 16 or higher at baseline 14. Current litigation of worker's compensation claim 15. Blood or clotting disorder 16. Acute infection (body temperature over 100 degrees F) 17. Current daily use of confounding-anti-inflammatory medication as part of regular medication regimen 18. Individuals that are not able to read & understand English |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | Congressionally Directed Medical Research Programs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in overall Gulf War Illness disease severity | Self reported Gulf War Illness symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no symptoms; 100=severe symptoms). | Average disease severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. | |
Secondary | Change from baseline in Pain Severity | Self reported pain severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no pain; 100=severe pain). | Average pain severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. | |
Secondary | Change from baseline in Fatigue Severity | Self reported fatigue severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=not fatigued at all; 100=severely fatigued). | Average fatigue severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. | |
Secondary | Change from baseline in Cognitive Symptom Severity | Self reported cognitive symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=not [able to think and remember] clearly at all; 100=[able to think and remember] very clearly). | Average cognitive symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. | |
Secondary | Change from baseline in Mood Symptom Severity | Self reported mood symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=not good [mood] at all; 100=extremely good [mood]). | Average mood severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. | |
Secondary | Change from baseline in Dermatological Symptom Severity | Self reported dermatological symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no skin problems at all; 100=severe skin problems). | Average dermatological symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. | |
Secondary | Change from baseline in Respiratory Symptom Severity | Self reported respiratory symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no breathing or respiratory problems at all; 100=severe breathing or respiratory problems). | Average respiratory symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. | |
Secondary | Change from baseline in Gastrointestinal Symptom Severity | Self reported gastrointestinal symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no bowel or GI problems at all; 100=severe bowel or GI problems). | Average gastrointestinal symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04254627 -
TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset
|
Phase 1 | |
Terminated |
NCT02011542 -
Probiotic (VSL #3) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078530 -
Probiotic (Visbiome) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT04058275 -
"Immunomodulation in GWI (Phlebotomy)"
|
||
Recruiting |
NCT04255498 -
Understanding GWI: Integrative Modeling
|
Phase 1 | |
Completed |
NCT02782780 -
Cognitive Behavioral Therapy for Insomnia for Gulf War Illness
|
N/A | |
Recruiting |
NCT02983734 -
D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)
|
Phase 2 | |
Recruiting |
NCT05972291 -
Mechanisms of Gulf War Illness
|
N/A | |
Recruiting |
NCT04182659 -
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|
N/A | |
Recruiting |
NCT04046536 -
rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI)
|
N/A | |
Recruiting |
NCT05377242 -
Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI
|
N/A | |
Recruiting |
NCT05675878 -
Confirmation of Diet as a Treatment for Gulf War Illness
|
Phase 3 | |
Recruiting |
NCT05736146 -
Validating Gulf War Illness Blood Biomarkers
|
||
Not yet recruiting |
NCT05820893 -
Resistant Potato Starch to Alleviate GWI
|
Phase 2 | |
Terminated |
NCT01846182 -
Research Examining Gulf War Illness in Our Nations Service Members
|
Phase 2 | |
Active, not recruiting |
NCT05252949 -
OEA for Targeting Lipid Metabolism in GWI
|
N/A | |
Completed |
NCT02378025 -
Treating Chronic Pain in Gulf War Illness
|
N/A | |
Completed |
NCT02865460 -
Coenzyme Q10 Phase III Trial in Gulf War Illness
|
Phase 3 | |
Completed |
NCT01291758 -
Exercise in Gulf War Illness (GWI)
|
||
Completed |
NCT01011348 -
Q10 for Gulf War Veterans
|
N/A |